Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfocamphocaine is an approved combination small molecule drug consisting of sulfocamphoric acid and procaine. It is primarily utilized as an analeptic and cardiovascular stimulant in Eastern Europe and Central Asia. The drug works by stimulating the respiratory and vasomotor centers in the medulla oblongata, which enhances pulmonary ventilation and increases peripheral vascular tone. It also has a direct positive effect on the myocardium, improving metabolic processes and increasing sensitivity to sympathetic impulses. Sulfocamphocaine is indicated for the treatment of acute and chronic heart failure, cardiogenic and septic shock, and respiratory depression. It is typically administered via subcutaneous, intramuscular, or intravenous injection as a 10% solution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfocamphocaine.